Table 1.
Intensive front-line therapy for young fit patient with mantle cell lymphoma (MCL)
| Regimen | Series | No. | Age(ys) Median (range) | MIPI Low/Int/High(%) | ORR (%) | CR (%) | mFU (ms) | mPFS (ms) | mOS (ms) | TRM (%) | Second malignancy(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R-hyper-CVAD/R-MA | Chihara (2016) [7, 27] | 65 | 56(41–65) | 5.52(4.87–6.91) Score | 97 (of 97 cases) | 89 | 13.4 ys | 6.5 ys | 13.4 ys | 6.5 | 26 |
| R-hyper-CVAD/R-MA | Merli (2012) [24] | 60 | 57(29–66) | 60/31/9 | 83 | 72 | 46 | 61% (5-y PFS) | 73% (5-y OS) | 5 | 1.6 |
| CHOP-Like + interferon-α VS. CHOP-Like + ASCT |
Dreyling(2005) [21] | 60 | 55(37–65) | 42/54/4 (IPI) | 99 Vs 98 | 37 Vs. 81 | 34 | 17 | 3-y OS, 77% | 0 | na |
| 62 | 56(35–65) | 44/49/7(IPI) | 39 | 3-y OS, 83% | 5 | na | |||||
| R-CHOP+ASCT Vs. R-CHOP/R-DHAP + HD-Ara-c + ASCT |
Hermine (2012) [31, 32] | 234 | 55 (48–60) | 60/26/14 | 97. Vs 97 | 63 Vs. 65 | 6.1ys | 3.9 ysa | 5-y OS, 40% | 3.4 | 5.2 |
| 232 | 56 (50–60) | 65/22/13 | 9.1 ysa | 5-y OS, 65% | 3.4 | 6.7 | |||||
| R-CHOP + MTX + R + HD-AraC/etoposide + ASCT | Damon (2009) [63] | 78 | 57 (37–69) | 53/31/15 (1 Unknown) | 88 | 69 | 4.7ys | 56% (5-y PFS) | 64% (5-y OS) | 2.6 | na |
| R-CHOP + HD-Ara-c + ASCT | Van’t Veer (2008) [64] | 87 | 55 (32–66) | 51/29/20 | 70 | 64 | 41.7 | 44% (4-y PFS) | 66% (4-y OS) | 6.9 | na |
| R-CHOP/R-DHAP + HD-Ara-c + ASCT | Delarue,2013 [33] | 60 | 57 (40–66) | 55/32/13 | 82 | 78 | 5.6ys | 64% (5-y EFS) | 75% (5-y OS) | 1.7 | 18 |
| R-DHAP + ASCT | Le Gouill (2014) [65] | 299 | 57 (27–65) | 53.2/27.4/19.4 | na | 92 | 35.8 | 74% (3-y PFS) | 83% (3-y OS) | na | na |
| R-CHOP+R-CTX + R-HD-Ara-c + ASCT +/− LEN | Cortelazzo(2015) [54] | 266 | 57 (51–61) | Int-High:53 | 86 | 77 | 19 | 77% (2-y PFS) | 88% (2-y OS) | 1.6 | na |
| R-maxi-CHOPb/HD-Ara-c + ASCT +/− R | Eskelund (2016) [9] | 159 | 56 (32–65) | 51/26/23 | 96 | 89.7 | 11.4ys | 8.5ys | 12.7ys | 7 | 12.6 |
| R-CHOP-14 + (R)ICE +ASCT | Schaffel (2010) [66] | 69 | < 60, 71% ≥60, 29% |
19/49/32 | na | na | 4.8ys | 65% (4-y PFS) | 84% (4-y OS) | 1 | na |
Abbreviations: HD-Ara-c high-dose cytarabine, ASCT autologous stem-cell transplantation, R rituximab, CR complete response, MIPI mantle cell lymphoma-international prognostic index, Int intermediate, mFU Median follow-up, mPFS median progression-free survival, EFS event-free survival, mOS median overall survival, ORR overall response rate, TRM treatment-related mortality; a TTF time to treatment failure
NR not reached, na not available, ne not evaluable, ms months, ys years, vs. versus
hyper-CVAD/MA, fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate-cytarabine;
DHAP, dexamethasone, cytarabine, carboplatin or cisplatin; bmaxi-CHOP: cyclophosphamide 1200 mg/m 2, doxorubicin 75 mg/m 2, vincristine 2 mg total day1;prednisone 100 mg days1–5; LEN: lenalidomide; ICE, ifosfamide, carboplatin, and etoposide